Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 13/20 | 0.59 |
| ▸ | RIPK3 | Q9Y572 | 6/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | AXL | P30530 | 6/20 | 0.54 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.52 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.52 |
| ▸ | MERTK | Q12866 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591297 | 0.83 | AXL (0.56) | METRIPK3AXL | |
| SCHEMBL4818940 | 0.82 | MET (0.79) | METRIPK3CYP3A4CYP2C9RIPK1 | |
| SCHEMBL2593106 | 0.82 | MET (0.59) | METLCKKITKDRFLT3 | |
| SCHEMBL4816591 | 0.80 | MET (0.76) | METRIPK3CYP3A4CYP2C9RIPK1 | |
| SCHEMBL10011780 | 0.80 | MET (0.50) | METRIPK3CYP3A4CYP2C9RIPK1 | |
| SCHEMBL16241072 | 0.79 | MET (0.63) | METRIPK3CYP3A4CYP2C9RIPK1 | |
| SCHEMBL1137557 | 0.79 | MET (0.79) | METRIPK3CYP3A4CYP2C9RIPK1 | |
| SCHEMBL1137189 | 0.79 | MET (0.65) | METRIPK3CYP3A4CYP2C9RIPK1 | |
| SCHEMBL1137273 | 0.78 | MET (0.76) | METRIPK3CYP3A4CYP2C9RIPK1 | |
| SCHEMBL12350029 | 0.77 | MET (0.67) | METRIPK3CYP3A4CYP2C9RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569319-B2 | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities | Deciphera Pharmaceuticals, LLS (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120172382-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC. (US) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172382-A1 | PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | MKI67, TYMP, CCNA1 | MET 2197/4885RIPK3 4032/4885CYP3A4 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.